HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,011,000 | -2.2% | 24,245 | +0.2% | 0.00% | 0.0% |
| Q4 2020 | $1,034,000 | +36.1% | 24,200 | -16.4% | 0.00% | +33.3% |
| Q3 2020 | $760,000 | -3.3% | 28,934 | -1.3% | 0.00% | -25.0% |
| Q2 2020 | $786,000 | +17.1% | 29,307 | -21.4% | 0.00% | 0.0% |
| Q1 2020 | $671,000 | -29.2% | 37,307 | -30.3% | 0.00% | -20.0% |
| Q4 2019 | $948,000 | +21.7% | 53,496 | +6.6% | 0.01% | +25.0% |
| Q3 2019 | $779,000 | -9.7% | 50,204 | 0.0% | 0.00% | -20.0% |
| Q2 2019 | $863,000 | -0.9% | 50,204 | -7.2% | 0.01% | -28.6% |
| Q1 2019 | $871,000 | -0.8% | 54,084 | -9.9% | 0.01% | +133.3% |
| Q4 2018 | $878,000 | -20.8% | 60,000 | -1.6% | 0.00% | -50.0% |
| Q3 2018 | $1,108,000 | +1.8% | 61,000 | -5.4% | 0.01% | 0.0% |
| Q2 2018 | $1,088,000 | -25.4% | 64,500 | -13.4% | 0.01% | -25.0% |
| Q1 2018 | $1,459,000 | – | 74,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |